Patent: 9,034,822
✉ Email this page to a colleague
Summary for Patent: 9,034,822
| Title: | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
| Abstract: | The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. |
| Inventor(s): | Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias LITZENBURGER, Keith Canada, Sanjaya Singh, Alisa Waterman |
| Assignee: | Boehringer Ingelheim International GmbH |
| Application Number: | US13/916,994 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,034,822
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | PRAXBIND | idarucizumab | Injection | 761025 | October 16, 2015 | ⤷ Start Trial | 2033-06-13 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,034,822
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201202876 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2011089183 | ⤷ Start Trial |
| Uruguay | 33196 | ⤷ Start Trial |
| United States of America | 2012027780 | ⤷ Start Trial |
| United States of America | 2013289248 | ⤷ Start Trial |
| United States of America | 2015210778 | ⤷ Start Trial |
| United States of America | 8486398 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
